Full-Time

Director Vulnerability Management

Posted on 9/10/2026

Deadline 10/16/26
Cencora

Cencora

10,001+ employees

Global pharmaceutical distribution and services provider

No salary listed

Carrollton, TX, USA + 1 more

More locations: Conshohocken, PA, USA

Remote

Bachelor's, Master's

Category
Cybersecurity (1)
Required Skills
Microsoft Windows
Computer Networking
Cybersecurity
Vulnerability Analysis
Penetration Testing
Linux/Unix

Get referred to Cencora

See people who can refer or advise you

Requirements
  • A bachelor's degree in Cybersecurity, Computer Science, Information Systems, or equivalent work experience.
  • At least 8 years of progressive cybersecurity experience, including at least 5 years in vulnerability management, security engineering, offensive security, or infrastructure security.
  • Experience leading technical teams and building or substantially maturing an enterprise-scale vulnerability or exposure management program.
  • Hands-on expertise with enterprise vulnerability management platforms such as Tenable, Qualys, Rapid7, or Wiz.
  • Strong working knowledge of operating system internals, networking, patch and configuration management, and enterprise identity across Windows, Linux, and macOS.
  • Experience securing public cloud environments and container technologies, including cloud-native vulnerability and posture management.
  • Fluency in vulnerability scoring and prioritization frameworks including CVSS, EPSS, CISA KEV, and SSVC.
  • Experience with application and software supply chain security concepts, including SAST, DAST, SCA, and SBOM.
  • Familiarity with NIST CSF, ISO 27001, and MITRE ATT&CK.
  • Excellent written and verbal communication skills, with the ability to influence engineering teams without direct authority and brief executive audiences credibly.
  • A bachelor's degree in cybersecurity, information technology, computer science, information systems, business administration, or a related field, or equivalent experience.
  • At least 10 years of experience in cybersecurity, information security, security operations, IT risk, or a related field.
  • At least 5 years of experience in a managerial capacity.
  • A certification in cybersecurity, information security, or a related field, such as CISSP, CISM, or an equivalent relevant certification.
Responsibilities
  • Own the strategy and continual development of the end-to-end vulnerability management program, including its strategy, roadmap, operating model, policy, standards, and success metrics.
  • Define and maintain risk-based remediation service-level agreements based on asset criticality, exposure, and severity.
  • Mature the program beyond reactive scanning toward continuous, risk-based exposure management, including attack surface management and validation of remediation effectiveness.
  • Establish governance forums to review exposure trends, aging findings, systemic root causes, and escalations.
  • Oversee comprehensive and accurate asset coverage by integrating scanning with the configuration management database, cloud inventories, and other asset discovery sources.
  • Lead refinement of prioritization models combining CVSS scoring with threat intelligence and exploitability signals, asset criticality, and compensating controls.
  • Partner with penetration testing, red team, threat intelligence, and countermeasures teams to correlate findings and validate control effectiveness.
  • Drive measurable reductions in mean time to remediate and aging critical exposures with IT operations, infrastructure, application, and cloud engineering teams.
  • Lead the technical response to zero-day and emerging critical vulnerabilities, including rapid impact assessments, containment guidance, and executive communication.
  • Identify and address systemic root causes such as patch tooling gaps, unsupported software, base image drift, and legacy platform debt.
  • Define and report key performance indicators and key risk indicators to executive leadership, translating technical exposure into business and financial risk.
  • Recruit, develop, mentor, and retain a team of vulnerability management analysts, building technical depth and clear career paths.
  • Set technical standards, review the team's work product, and cultivate a culture of data quality and continuous improvement.
Desired Qualifications
  • GIAC GEVA certification.
  • GIAC GPEN certification.
  • CISSP certification.
  • CISM certification.
  • A master's degree in cybersecurity, information technology, computer science, information systems, business administration, or a related field, or equivalent experience.
  • Certified Cloud Security Professional (CCSP), Certified Ethical Hacker (CEH), or an equivalent certification.

Cencora provides global pharmaceutical distribution and a range of services, including specialty pharmacy, consulting, supply-chain management, patient support programs, and data analytics for healthcare providers, manufacturers, and veterinary practices. It works by combining physical drug distribution with value-added services such as inventory management, regulatory compliance guidance, patient support, and data-driven insights to optimize supply chains and outcomes. The company differentiates itself with an integrated, end-to-end offering that spans distribution, clinical services, analytics, and advisory support to help clients run more efficient operations and lower costs. Its goal is to improve healthcare outcomes by delivering comprehensive pharmaceutical solutions that enable better care and lower overall expenses.

Company Size

10,001+

Company Stage

IPO

Headquarters

Pennsylvania

Founded

1907

Get referred to Cencora

See people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • Fiscal 2026 Q3 revenue reached $84.8 billion, and EPS guidance rose to $17.75-$17.95.
  • Cencora completed OneOncology in February 2026, strengthening specialty-pharmacy and oncology economics.
  • A $7 billion revolver and $1 billion buyback show lenders and management backing execution.

What critics are saying

  • Opioid litigation still carries a $4.2 billion accrued liability through 2039.
  • Maryland courts vacated Baltimore's $152 million verdict, but appeals can revive distributor exposure.
  • ASP rule changes and 340B guidance threaten community-oncology margins by 2028, hitting OneOncology.

What makes Cencora unique

  • Cencora pairs drug distribution with OneOncology, deepening specialty-care workflow integration.
  • Its global network spans U.S. Healthcare Solutions and International Healthcare Solutions across 51,000 employees.
  • Nucleus inventory tools and cell-gene therapy enablement embed Cencora inside provider operations.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Health Insurance

Dental Insurance

Vision Insurance

Paid Parental Leave

Adoption Assistance

Infertility Coverage

Family Planning Benefits

Behavioral Health Solutions

Professional Development Budget

Training Programs

Company News

Associated Press
Sep 2nd, 2026
Cencora launches cell and gene therapy service to help health systems scale advanced treatment programmes

Cencora has launched Cell and Gene Therapy Enablement through its Accelerate Pharmacy Solutions division to help health systems develop and expand cell and gene therapy programmes. The service provides support across financial planning, operational readiness, and scalable growth to reduce care barriers and improve patient access to advanced therapies. More than 35 cell and gene therapies have received FDA approval, with over 1,700 clinical trials underway globally. However, only 4% of health system pharmacy leaders report being fully prepared to integrate these treatments, highlighting infrastructure gaps. The offering includes market assessments, readiness evaluations, governance design, and workflow planning. Cencora, ranked number 10 on the Fortune 500 with over $300 billion in annual revenue, already provides specialty pharmaceutical services across the therapy lifecycle.

Yahoo Finance
Aug 14th, 2026
Cencora beats Q2 profit estimates as specialty pharma platform drives growth

Cencora reported second-quarter revenue of $84.75 billion, slightly above analyst estimates of $84.43 billion, representing 5.1% year-on-year growth. Adjusted earnings per share came in at $4.48, beating consensus estimates of $4.35 by 3%. Management attributed the performance to strength in specialty pharmaceuticals, particularly through Management Services Organisations like OneOncology and RCA. CEO Robert Mauch highlighted the company's positioning in specialty care, stating, "Our specialty platform supports growth across the healthcare ecosystem." The company raised its full-year adjusted EPS guidance to $17.85 at the midpoint. Operating margin held steady at 1.3%, matching the same quarter last year. During the earnings call, analysts questioned management about biosimilar opportunities, specialty logistics competition, and potential policy risks from proposed ASP rule changes.

Yahoo Finance
Aug 12th, 2026
Cencora raises FY2026 guidance after Q3 EPS jumps 12%, buys back $1B in shares

Cencora reported strong third-quarter results for fiscal year 2026, driven by execution across its business units and investments in its specialty positioning. The pharmaceutical distributor achieved double-digit adjusted operating income growth and 12% earnings per share growth in the quarter. The company conducted $1 billion in opportunistic share repurchases during the period. Based on its performance and confidence in continued execution, Cencora raised its fiscal 2026 EPS guidance. President and CEO Robert Mauch credited the results to the company's team members and their commitment to providing solutions for customers. He highlighted the strength of Cencora's portfolio and its pharmaceutical-centric strategy as the company approaches the end of its fiscal year. The earnings call was held on 5 August 2026, with senior leadership including Mauch and CFO Eva Boratto participating.

MarketScreener
Aug 5th, 2026
Cencora boosts credit facility to $7B, extends maturity to 2031

Cencora and its subsidiary Innomar Strategies have amended their credit agreement, increasing their multi-currency revolving credit facility from $5.5 billion to $7.0 billion. The facility's maturity date has been extended to July 2031. Interest rates on borrowings range from 69.5 to 110 basis points over various term rates, depending on Cencora's public debt ratings. The agreement includes covenants such as a maximum financial leverage ratio. Separately, on 31 July 2026, Cencora amended its receivables securitisation facility, reducing it from $1.5 billion to $1.0 billion whilst increasing the accordion feature from $500 million to $1.0 billion. This gives the company the option to expand commitments by up to $1.0 billion, subject to bank approval.

Yahoo Finance
Aug 1st, 2026
Cencora Q3 earnings preview: analysts expect $4.37 EPS on $84.89B revenue

Wall Street analysts expect Cencora to report quarterly earnings of $4.37 per share, marking a 9.3% year-over-year increase. Revenues are projected to reach $84.89 billion, up 5.2% from the same quarter last year. Over the past 30 days, the consensus earnings per share estimate has been revised upward by 1.3%. Analysts forecast revenue from Total US Healthcare Solutions at $75 billion, representing 2.9% year-over-year growth. International Healthcare Solutions revenue is expected to remain flat at $7.79 billion. Operating income projections show US Healthcare Solutions at $940.87 million and International Healthcare Solutions at $158.45 million. Cencora shares have risen 5.3% over the past month and hold a Zacks Rank of 2, indicating expected outperformance versus the broader market.